首页> 美国卫生研究院文献>Scientific Reports >An Integrated Local Classification Model of Predicting Drug-Drug Interactions via Dempster-Shafer Theory of Evidence
【2h】

An Integrated Local Classification Model of Predicting Drug-Drug Interactions via Dempster-Shafer Theory of Evidence

机译:基于Dempster-Shafer证据理论预测药物相互作用的集成局部分类模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Drug-drug interactions (DDIs) may trigger adverse drug reactions, which endanger the patients. DDI identification before making clinical medications is critical but bears a high cost in clinics. Computational approaches, including global model-based and local model based, are able to screen DDI candidates among a large number of drug pairs by utilizing preliminary characteristics of drugs (e.g. drug chemical structure). However, global model-based approaches are usually slow and don’t consider the topological structure of DDI network, while local model-based approaches have the degree-induced bias that a new drug tends to link to the drug having many DDI. All of them lack an effective ensemble method to combine results from multiple predictors. To address the first two issues, we propose a local classification-based model (LCM), which considers the topology of DDI network and has the relaxation of the degree-induced bias. Furthermore, we design a novel supervised fusion rule based on the Dempster-Shafer theory of evidence (LCM-DS), which aggregates the results from multiple LCMs. To make the final prediction, LCM-DS integrates three aspects from multiple classifiers, including the posterior probabilities output by individual classifiers, the proximity between their instance decision profiles and their reference profiles, as well as the quality of their reference profiles. Last, the substantial comparison with three state-of-the-art approaches demonstrates the effectiveness of our LCM, and the comparison with both individual LCM implementations and classical fusion algorithms exhibits the superiority of our LCM-DS.
机译:药物相互作用(DDI)可能会触发药物不良反应,从而危及患者。在制作临床药物之前进行DDI识别非常关键,但是在临床上成本很高。计算方法,包括基于全局模型和基于局部模型的方法,能够通过利用药物的初步特征(例如药物化学结构)来筛选大量药物对中的DDI候选物。但是,基于全局模型的方法通常速度较慢,并且不考虑DDI网络的拓扑结构,而基于局部模型的方法具有程度引起的偏差,即新药倾向于与具有许多DDI的药物相关联。他们都缺乏有效的综合方法来合并多个预测变量的结果。为了解决前两个问题,我们提出了一种基于局部分类的模型(LCM),该模型考虑了DDI网络的拓扑结构,并且具有程度引起的偏差的松弛。此外,我们基于Dempster-Shafer证据理论(LCM-DS)设计了一种新颖的监督融合规则,该规则汇总了多个LC​​M的结果。为了做出最终预测,LCM-DS集成了来自多个分类器的三个方面,包括各个分类器输出的后验概率,其实例决策配置文件和其参考配置文件之间的接近度以及它们的参考配置文件的质量。最后,与三种最先进方法的实质比较证明了我们的LCM的有效性,与单独的LCM实现和经典融合算法的比较都显示了我们的LCM-DS的优越性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号